Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 5/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.70 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.49 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036352 | 0.83 | CHRNB4 (0.73) | CHRNB4CHRNA3EHMT2CHRNB2CHRNA4 | |
| SCHEMBL4269812 | 0.79 | PDE4B (0.62) | MAPK1 | |
| SCHEMBL8795514 | 0.78 | CHRNB4 (0.66) | CHRNB4CHRNA3MCHR1CHRNB2CHRNA4 | |
| SCHEMBL8795523 | 0.78 | CHRNB4 (0.66) | CHRNB4CHRNA3MCHR1CHRNB2CHRNA4 | |
| SCHEMBL5090042 | 0.78 | PARP15 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL12409070 | 0.78 | CHRNB4 (0.69) | CHRNB4CHRNA3MCHR1EHMT2CHRNB2 | |
| SCHEMBL32691730 | 0.77 | CHRNB4 (0.62) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL32691652 | 0.77 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL10196599 | 0.76 | CHRNB4 (0.71) | CHRNB4CHRNA3MCHR1CHRNB2CHRNA4 | |
| SCHEMBL6944744 | 0.76 | MAPK1 (0.63) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | SMITHKLINE BEECHAM P.L.C. | 2003-04-10 | — | — | US | claimed |
| CN-1246116-A | Sulfonamide derivatives, process for their preparation and their use as medicaments | SMITHKLINE BEECHAM PLC (GB) | 2000-03-01 | — | — | CN | claimed |
| EP-0946539-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027081-A1 | SULPHONAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-06-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069233-A1 | Sulphonamide derivatives, process for their preparation, and their use as medicaments | TPMT, MPST, STS | CHRNB4 1753/4885CHRNA3 2095/4885MCHR1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.